Comparison of the effectiveness of frontline chemoimmunotherapy regimens for follicular lymphoma used in the United States

Loretta J. Nastoupil, Rajni Sinha, Michelle Byrtek, Ryan Ziemiecki, Michael Taylor, Jonathan W. Friedberg, Jean L. Koff, Brian K. Link, James R Cerhan, Keith L. Dawson, Christopher R. Flowers

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

To compare the effectiveness of frontline rituximab-chemotherapy regimens in clinical practice, we examined outcomes for patients with low-grade, stage III/IV follicular lymphoma receiving rituximab (R) with cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP), R with cyclophosphamide, vincristine and prednisone (R-CVP) or R with a fludarabine-based regimen (R-Flu) as frontline therapy. In total, 611 patients meeting these criteria were identified in the National LymphoCare Study: 47% receiving R-CHOP (n = 287), 31% receiving R-CVP (n = 187) and 22% receiving R-Flu (n = 137). Overall response rates were high (R-CVP 87%, R-CHOP 93%, R-Flu 94%; p = 0.017). Median follow-up was 7.4 years. R-CVP was associated with lower 5-year overall survival (R-CVP 76%, R-CHOP 86%, R-Flu 86%; p = 0.021) and progression-free survival (R-CVP 49%, R-CHOP 58%, R-Flu 64%; p = 0.029). There were no significant differences in survival in Cox models adjusted for baseline clinical factors, practice region/setting and post-treatment R maintenance/observation.

Original languageEnglish (US)
Pages (from-to)1295-1302
Number of pages8
JournalLeukemia and Lymphoma
Volume56
Issue number5
DOIs
StatePublished - May 1 2015

Fingerprint

Follicular Lymphoma
Vincristine
Prednisone
Cyclophosphamide
Survival
Proportional Hazards Models
Doxorubicin
Disease-Free Survival
Maintenance
Observation
Drug Therapy
Therapeutics

Keywords

  • Chemotherapy
  • Follicular lymphoma
  • Frontline
  • Outcomes
  • Rituximab

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Nastoupil, L. J., Sinha, R., Byrtek, M., Ziemiecki, R., Taylor, M., Friedberg, J. W., ... Flowers, C. R. (2015). Comparison of the effectiveness of frontline chemoimmunotherapy regimens for follicular lymphoma used in the United States. Leukemia and Lymphoma, 56(5), 1295-1302. https://doi.org/10.3109/10428194.2014.953144

Comparison of the effectiveness of frontline chemoimmunotherapy regimens for follicular lymphoma used in the United States. / Nastoupil, Loretta J.; Sinha, Rajni; Byrtek, Michelle; Ziemiecki, Ryan; Taylor, Michael; Friedberg, Jonathan W.; Koff, Jean L.; Link, Brian K.; Cerhan, James R; Dawson, Keith L.; Flowers, Christopher R.

In: Leukemia and Lymphoma, Vol. 56, No. 5, 01.05.2015, p. 1295-1302.

Research output: Contribution to journalArticle

Nastoupil, LJ, Sinha, R, Byrtek, M, Ziemiecki, R, Taylor, M, Friedberg, JW, Koff, JL, Link, BK, Cerhan, JR, Dawson, KL & Flowers, CR 2015, 'Comparison of the effectiveness of frontline chemoimmunotherapy regimens for follicular lymphoma used in the United States', Leukemia and Lymphoma, vol. 56, no. 5, pp. 1295-1302. https://doi.org/10.3109/10428194.2014.953144
Nastoupil, Loretta J. ; Sinha, Rajni ; Byrtek, Michelle ; Ziemiecki, Ryan ; Taylor, Michael ; Friedberg, Jonathan W. ; Koff, Jean L. ; Link, Brian K. ; Cerhan, James R ; Dawson, Keith L. ; Flowers, Christopher R. / Comparison of the effectiveness of frontline chemoimmunotherapy regimens for follicular lymphoma used in the United States. In: Leukemia and Lymphoma. 2015 ; Vol. 56, No. 5. pp. 1295-1302.
@article{44784dfd3b9e43e5b9ca1d7f12b821d1,
title = "Comparison of the effectiveness of frontline chemoimmunotherapy regimens for follicular lymphoma used in the United States",
abstract = "To compare the effectiveness of frontline rituximab-chemotherapy regimens in clinical practice, we examined outcomes for patients with low-grade, stage III/IV follicular lymphoma receiving rituximab (R) with cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP), R with cyclophosphamide, vincristine and prednisone (R-CVP) or R with a fludarabine-based regimen (R-Flu) as frontline therapy. In total, 611 patients meeting these criteria were identified in the National LymphoCare Study: 47{\%} receiving R-CHOP (n = 287), 31{\%} receiving R-CVP (n = 187) and 22{\%} receiving R-Flu (n = 137). Overall response rates were high (R-CVP 87{\%}, R-CHOP 93{\%}, R-Flu 94{\%}; p = 0.017). Median follow-up was 7.4 years. R-CVP was associated with lower 5-year overall survival (R-CVP 76{\%}, R-CHOP 86{\%}, R-Flu 86{\%}; p = 0.021) and progression-free survival (R-CVP 49{\%}, R-CHOP 58{\%}, R-Flu 64{\%}; p = 0.029). There were no significant differences in survival in Cox models adjusted for baseline clinical factors, practice region/setting and post-treatment R maintenance/observation.",
keywords = "Chemotherapy, Follicular lymphoma, Frontline, Outcomes, Rituximab",
author = "Nastoupil, {Loretta J.} and Rajni Sinha and Michelle Byrtek and Ryan Ziemiecki and Michael Taylor and Friedberg, {Jonathan W.} and Koff, {Jean L.} and Link, {Brian K.} and Cerhan, {James R} and Dawson, {Keith L.} and Flowers, {Christopher R.}",
year = "2015",
month = "5",
day = "1",
doi = "10.3109/10428194.2014.953144",
language = "English (US)",
volume = "56",
pages = "1295--1302",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "5",

}

TY - JOUR

T1 - Comparison of the effectiveness of frontline chemoimmunotherapy regimens for follicular lymphoma used in the United States

AU - Nastoupil, Loretta J.

AU - Sinha, Rajni

AU - Byrtek, Michelle

AU - Ziemiecki, Ryan

AU - Taylor, Michael

AU - Friedberg, Jonathan W.

AU - Koff, Jean L.

AU - Link, Brian K.

AU - Cerhan, James R

AU - Dawson, Keith L.

AU - Flowers, Christopher R.

PY - 2015/5/1

Y1 - 2015/5/1

N2 - To compare the effectiveness of frontline rituximab-chemotherapy regimens in clinical practice, we examined outcomes for patients with low-grade, stage III/IV follicular lymphoma receiving rituximab (R) with cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP), R with cyclophosphamide, vincristine and prednisone (R-CVP) or R with a fludarabine-based regimen (R-Flu) as frontline therapy. In total, 611 patients meeting these criteria were identified in the National LymphoCare Study: 47% receiving R-CHOP (n = 287), 31% receiving R-CVP (n = 187) and 22% receiving R-Flu (n = 137). Overall response rates were high (R-CVP 87%, R-CHOP 93%, R-Flu 94%; p = 0.017). Median follow-up was 7.4 years. R-CVP was associated with lower 5-year overall survival (R-CVP 76%, R-CHOP 86%, R-Flu 86%; p = 0.021) and progression-free survival (R-CVP 49%, R-CHOP 58%, R-Flu 64%; p = 0.029). There were no significant differences in survival in Cox models adjusted for baseline clinical factors, practice region/setting and post-treatment R maintenance/observation.

AB - To compare the effectiveness of frontline rituximab-chemotherapy regimens in clinical practice, we examined outcomes for patients with low-grade, stage III/IV follicular lymphoma receiving rituximab (R) with cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP), R with cyclophosphamide, vincristine and prednisone (R-CVP) or R with a fludarabine-based regimen (R-Flu) as frontline therapy. In total, 611 patients meeting these criteria were identified in the National LymphoCare Study: 47% receiving R-CHOP (n = 287), 31% receiving R-CVP (n = 187) and 22% receiving R-Flu (n = 137). Overall response rates were high (R-CVP 87%, R-CHOP 93%, R-Flu 94%; p = 0.017). Median follow-up was 7.4 years. R-CVP was associated with lower 5-year overall survival (R-CVP 76%, R-CHOP 86%, R-Flu 86%; p = 0.021) and progression-free survival (R-CVP 49%, R-CHOP 58%, R-Flu 64%; p = 0.029). There were no significant differences in survival in Cox models adjusted for baseline clinical factors, practice region/setting and post-treatment R maintenance/observation.

KW - Chemotherapy

KW - Follicular lymphoma

KW - Frontline

KW - Outcomes

KW - Rituximab

UR - http://www.scopus.com/inward/record.url?scp=84932139921&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84932139921&partnerID=8YFLogxK

U2 - 10.3109/10428194.2014.953144

DO - 10.3109/10428194.2014.953144

M3 - Article

C2 - 25263322

AN - SCOPUS:84932139921

VL - 56

SP - 1295

EP - 1302

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 5

ER -